Xenon PharmaceuticalsXENE +5.21%25 Current Ratio is 27.79 as of Mar. 2026, which is 54% above its 10-year median of 18.09. GuruFocus rates XENE with a GF Score™ of 25/100. The stock has 5 warning signs investors should review. Among 1,416 Biotechnology companies, Xenon Pharmaceuticals ranks better than 95.76% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Xenon Pharmaceuticals's current ratio for the quarter that ended in Mar. 2026 was 27.79.
Xenon Pharmaceuticals has a current ratio of 27.79. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Xenon Pharmaceuticals's Current Ratio or its related term are showing as below:
XENE'
s Current Ratio Range Over the Past 10 Years
Min: 3.34 Med: 18.09 Max: 68.36
Current: 27.79
During the past 13 years, Xenon Pharmaceuticals's highest Current Ratio was 68.36. The lowest was 3.34. And the median was 18.09.
XENE's Current Ratio is ranked better than 95.76% of 1416
companies
in the Biotechnology industry
Industry Median: 3.885
vs XENE: 27.79
Xenon Pharmaceuticals (NAS:XENE) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Xenon Pharmaceuticals Current Ratio Related Terms
Xenon Pharmaceuticals Current Ratio Historical Data
* Premium members only.
The historical data trend for Xenon Pharmaceuticals's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XENE vs CRSP, CGON, DNTH: Current Ratio Comparison
For the Biotechnology subindustry, Xenon Pharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xenon Pharmaceuticals Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xenon Pharmaceuticals's Current Ratio distribution charts can be found below:
* The bar in red indicates where Xenon Pharmaceuticals's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xenon Pharmaceuticals (XENE) has a Current Ratio of 27.79 as of Mar. 2026. This is 54% above median its historical median of 18.09. Over the past decade, Xenon Pharmaceuticals' Current Ratio has ranged from 3.34 to 68.36. According to the industry distribution chart, Xenon Pharmaceuticals ranks #60 out of 1416 companies in the Biotechnology industry, placing it in the top 4.2%.
Is Xenon Pharmaceuticals' Current Ratio too high?
Xenon Pharmaceuticals' current Current Ratio of 27.79 is 54% above median its 10-year median of 18.09. Over the past 10 years, this metric has ranged from a low of 3.34 to a high of 68.36. The Biotechnology industry median Current Ratio is 3.89. Xenon Pharmaceuticals' value of 27.79 is 615.3% above this industry median. Based on the distribution chart, Xenon Pharmaceuticals ranks #60 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Xenon Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Xenon Pharmaceuticals' Current Ratio compare to CRSP and CGON?
According to the Biotechnology industry distribution chart, Xenon Pharmaceuticals ranks #60 out of 1416 companies for Current Ratio. This places Xenon Pharmaceuticals in the top 4% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.89. Xenon Pharmaceuticals' value of 27.79 is 615.3% above this benchmark. Historically, Xenon Pharmaceuticals' own Current Ratio has ranged from 3.34 to 68.36 over the past decade. While the company's 10-year median is 18.09 vs. the industry median of 3.89, Xenon Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xenon Pharmaceuticals's current Current Ratio of 27.79 is 615.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xenon Pharmaceuticals's current Current Ratio is 27.79, which is 54% above median its own 10-year median of 18.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xenon Pharmaceuticals stock overvalued right now?
Xenon Pharmaceuticals (XENE) has a current Current Ratio of 27.79. The current Current Ratio is 27.79, which is 54% above median its 10-year median of 18.09 and 615.3% above the Biotechnology industry median of 3.89. Xenon Pharmaceuticals' overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Xenon Pharmaceuticals (XENE), the current Current Ratio is 27.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
25GF Score
Get the complete analysis for XENE
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XENE has been successfully added to your 
